Oncotarget

Research Papers:

MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways

Xin Kong, Fengchao Liu and Jian Gao _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2016; 7:66051-66060. https://doi.org/10.18632/oncotarget.11800

Metrics: PDF 737 views  |   HTML 873 views  |   ?  


Abstract

Xin Kong1, Fengchao Liu1, Jian Gao1

1Department of Gastroenterology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China

Correspondence to:

Jian Gao, email: 982213482@qq.com

Keywords: epithelial-mesenchymal transition, SGK3, miR-155, hepatocellular carcinoma, phosphatidylinositol-3-kinase

Received: March 01, 2016    Accepted: August 24, 2016    Published: September 01, 2016

ABSTRACT

Oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of phosphoinositide 3-kinase (PI3K), occur with high frequency in hepatocellular carcinoma (HCC). The protein kinase Akt is considered to be the primary effector of PI3K, but there is evidence to suggest that serum and glucocorticoid kinase 3 (SGK3) acts in an Akt-independent manner downstream of PI3K. In this report, we found that SGK3 promotes epithelial-mesenchymal transition (EMT) and reduces phosphorylation-dependent degradation of β-catenin in HCC cells. We determined that miR-155, previously shown to promote EMT, stimulates the expression of SGK3 by targeting and repressing P85α, thereby removing its inhibitory effect on PI3K-AKT signaling. These findings suggest that miR-155 promotes EMT and metastatic properties in HCC cells through activation of PI3K/SGK3/β-catenin signaling pathways.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11800